European CHMP approval of fingolimod (Mylan) for treatment of relapsing-remitting multiple sclerosis with high disease activity

Fingolimod Mylan is a generic, bioequivalent to Gilenya and will be licensed for the same indications.

Source:

European Medicines Agency